Boundless Bio, Inc. (BOLD)
NASDAQ: BOLD · Real-Time Price · USD
2.710
+0.020 (0.74%)
At close: Nov 20, 2024, 4:00 PM
2.840
+0.130 (4.80%)
After-hours: Nov 20, 2024, 6:55 PM EST
Boundless Bio Employees
Boundless Bio had 72 employees as of December 31, 2023.
Employees
72
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$848,042
Market Cap
60.43M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 72 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 389 |
| bluebird bio | 375 |
| Exagen | 179 |
| Mural Oncology | 117 |
| Immuneering | 68 |
| IO Biotech | 68 |
| Cellectar Biosciences | 20 |
| Entera Bio | 18 |
BOLD News
- 13 days ago - Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 16 days ago - Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 6 months ago - Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 6 months ago - Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights - Business Wire
- 7 months ago - Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 - Business Wire
- 8 months ago - Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications - Business Wire